MorphoSys Targets 2020 Tafasitamab Launch Following Good DLBCL Data
Executive Summary
Morphosys says good L-MIND Phase II data back its plan to submit a US BLA to the US Food and Drug Administration by year-end, for a potential mid-2020 approval of tafasitamab.
You may also be interested in...
ADC’s Phase II Data May Position ‘Lonca’ To Compete With Roche’s Polivy
The antibody-drug conjugate yields a 48% overall and 24% complete response rate in a pivotal Phase II DLBCL study. The Swiss biotech hopes to compete with Polivy and is studying combo therapy with Imbruvica.
MorphoSys Chooses Incyte As Its Global Tafasitamab Partner
MorphoSys has chosen Incyte as its global partner for commercializing and further developing its lead asset, the Fc-engineered antibody tafasitamab that targets CD19.
New CEO At MorphoSys Seeking Partner For ‘CAR-T Killer’ Lymphoma Drug
Analysts tip Munich-based company for greatness, but it will need a big pharma partner to take on Roche's Polivy in competitive hemato-oncology market.